FDA approves label update for Roche's Mabthera/Rituxan (rituximab)
Roche announced the FDA has approved an update to the MabThera/Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment. October 19, 2018